Will joined Insmed in 2012 as President and Chief Executive Officer and as a member of the board of directors. He became Chair of the Board of Directors in November 2018. Will is the former Co-Founder, President, and Chief Financial Officer of Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR), and previously spent more than 10 years working in investment banking in the U.S. and Europe. He also previously worked for the U.S. government.
Will holds a Bachelor of Arts degree cum laude from Oberlin College as well as a Master of Business Administration and a Juris Doctor with Honors from Case Western Reserve University. Will serves as Chair of the Board of Directors of Adrestia Therapeutics, a private UK-based company focused on synthetic rescue therapies for genetic diseases, as a member of the Board of Trustees of Case Western Reserve University, and as a member of the Board of Trustees of BioNJ, the life sciences association for New Jersey.
